Table 1. In vitro potency and hypoxia cytotoxicity ratio (HCR) in A549 human cancer cell line.

Compound	IC50 [oxic] (μM) ± SEMa,b	IC50 [anoxic] (μM) ± SEMa,b	HCR
TPZ (1)	63.5	7.1	8.9
OXi6196 (2)	0.0066c	NDd	NDd
KGP18 (3)	0.000027c	NDd	NDd
OXi8006 (4)	0.030c	NDd	NDd
KGP24 (12)	0.46 ± 0.05	0.48 ± 0.04	1.0
KGP25 (13)	2.74 ± 1.13	0.25 ± 0.08	11.0
KGP66 (14)	0.13 ± 0.06	0.05 ± 0.01	2.6
KGP105 (15)	0.25 ± 0.02	0.04 ± 0.003	6.2
KGP291 (16)	0.38 ± 0.03	0.05 ± 0.004	7.6
KGP30 (17)e	NDd	NDd	NDd
KGP29 (18)e	NDd	NDd	NDd
KGP305 (19)	0.05 ± 0.005	0.22 ± 0.09	0.2
KGP304 (20)	2.27 ± 1.01	0.38 ± 0.12	6.0
KGP293 (21)	0.36 ± 0.02	0.04 ± 0.005	9.0
KGP292 (22)	0.67 ± 0.13	0.14 ± 0.04	4.8
KGP311 (23)	5.58 ± 3.59	0.07 ± 0.04	79.7
KGP343 (24)	4.06 ± 1.89	0.12 ± 0.06	33.8
KGP354 (25)	5.53 ± 2.22	0.07 ± 0.02	79

^aAverage of n ≥ 3 independent determinations.

^b4 h incubation (oxic or anoxic) followed by 48 h oxic exposure.

^cValues for standard SRB assay for cytotoxicity in A549 cells.

^dND = not determined.

^eSee Table S3 for HCR data under different assay conditions.